Supplemental online content for:

**NCCN Guidelines for Ovarian Cancer, Version 2.2020**

Deborah K. Armstrong, MD; Ronald D. Alvarez, MD; Jamie N. Bakkum-Gamez, MD; Lisa Barroilhet, MD; Kian Behbakht, MD; Andrew Berchuck, MD; Lee-may Chen, MD; Mihaela Cristea, MD; Maria DeRosa, RN; Eric L. Eisenhauer, MD; David M. Gershenson, MD; Heidi J. Gray, MD; Rachel Grisham, MD; Ardeshir Hakam, MD; Angela Jain, MD; Amer Karam, MD; Gottfried E. Konecny, MD; Charles A. Leath III, MD; Joyce Liu, MD, MPH; Haider Mahdi, MD, MPH; Lainie Martin, MD; Daniela Matei, MD; Michael McHale, MD; Karen McLean, MD, PhD; David S. Miller, MD; David M. O’Malley, MD; Sanja Percac-Lima, MD, PhD; Elena Ratner, MD; Steven W. Remmenga, MD; Roberto Vargas, MD; Theresa L. Werner, MD; Emese Zsiros, MD, PhD; Jennifer L. Burns; and Anita M. Engh, PhD


**eTable 1:** IV Chemotherapy: Randomized Trials Comparing Paclitaxel 175/Carboplatin With Other Doublet Combinations

**eTable 2:** IV Chemotherapy: Randomized Trials Comparing Paclitaxel 175/Carboplatin With Triplet/Quadruplet Combinations
### eTable 1. IV Chemotherapy: Randomized Trials Comparing Paclitaxel 175/Carboplatin with Other Doublet Combinations

<table>
<thead>
<tr>
<th>Trial</th>
<th>Stage</th>
<th>N</th>
<th>Dosing per Cycle</th>
<th>Cycle Length, wk</th>
<th>No. of Cycles</th>
<th>Efficacy</th>
<th>Safety/QoL</th>
</tr>
</thead>
</table>
| Dutch/Danish RCT1,2           | IIB–IV      | 208| Paclitaxel, 175 mg/m² D1 + cisplatin, 75 mg/m² D1 | 3                | 6             | NS       | • More nausea, vomiting, peripheral neurotoxicity  
• Less granulocytopenia and thrombocytopenia |
| GOG-1581,2                    | III         | 792| Paclitaxel, 135 mg/m² D1 + cisplatin, 75 mg/m² D1 | 3                | 6             | NS       | • More GI, renal, and metabolic toxicity  
• Less thrombocytopenia               |
| AGO-OVAR-3+                 | IIB–IV      | 798| Paclitaxel, 185 mg/m² D1 + cisplatin, 175 mg/m² D1 | 3                | 6             | NS       | • More nausea/vomiting, appetite loss, fatigue, and neurotoxicity  
• Less hematologic toxicity  
• Worse overall QoL, physical functioning, role functioning, cognitive functioning |
| ChiCTR-TRC-110013337         | II–IV       | 182| Paclitaxel, 175 mg/m² D1 + nedaplatin, 80 mg/m² D1 | 3                | 6             | ITT: NS  
Stage III–IV: better PFS (P = .02); NS OS | • Less grade 3/4 leukopenia |

Abbreviations: AUC, area under the curve; D, day of cycle; GI, gastrointestinal; ITT, intention to treat; NS, no significant difference between arms; OS, overall survival; PFS, progression-free survival; QoL, quality of life; RCT, randomized controlled trial.

*aEach of the trials used the following regimen as comparator: paclitaxel, 175 mg/m² + carboplatin, AUC 5–6, both D1, q3wk x 6 cycles.

*bDoublets not recommended in the NCCN Guidelines.

cTotal number of patients randomized, including those in the paclitaxel 175/carboplatin control arm.

*dTest regimen compared with paclitaxel 175/carboplatin.

*eToxicity or QoL compared with paclitaxel 175/carboplatin.

fNS indicates no significant difference between regimens for PFS and/or OS.

gToxicity or QoL compared with paclitaxel 175/carboplatin.

### References
Table 2. IV Chemotherapy: Randomized Trials Comparing Paclitaxel 175/Carboplatin® With Triplet/Quadruplet Combinations

<table>
<thead>
<tr>
<th>Trial</th>
<th>Stage</th>
<th>N</th>
<th>Dosing per Cycle</th>
<th>Cycle Length, wk</th>
<th>No. of Cycles</th>
<th>Efficacy</th>
<th>Safety/QoL</th>
</tr>
</thead>
</table>
| ICON3                        | IC–IV | 653| Cyclophosphamide, 500 mg/m² D1 + doxorubicin, 50 mg/m² D1 + cisplatin, 50 mg/m² D1 | 3                | 6            | NS       | • More nausea/vomiting, fever  
                                      |       |    |                                                                                 |                  |              |          | • Less sensory neuropathy |
| HeCOG RCT                    | IIC–IV| 247| Paclitaxel, 175 mg/m² D1 + carboplatin, AUC 7 D1 cycles 1, 3, 5+ cisplatin, 75 mg/m² D1 cycles 2, 4, 6 | 3                | 6            | NS       | • More severe nausea/vomiting |
| AGO-OCSG RCT                 | II–IV | 1,282| Paclitaxel, 175 mg/m² D1 + carboplatin, AUC 5 D1 + epirubicin, 60 mg/m² D1       | 3                | 6            | NS       | • More nausea/emesis, mucositis, infections, and grade 3/4 hematologic toxicities  
                                      |       |    |                                                                                 |                  |              |          | • Worse QoL |
| NCT00102375                 | II–IV | 1,308| Paclitaxel, 175 mg/m² D1 cycles 1–6 + carboplatin, AUC 5 D1 cycles 1–6 + topotecan, 1.25 mg/m² D1 cycles 1–6 + topotecan, 1.25 mg/m² D1 cycles 7–10 | 3                | ≤10          | NS       | • More grade 3/4 hematologic toxicities and grade 3/4 infections |
| GOG-0182-ICON5               | III–IV| 4,312| Paclitaxel, 175 mg/m² D1 + carboplatin, AUC 5 D1 + gemcitabine, 800 mg/m² D1    | 3                | 8            | NS       | • More neutropenia, thrombocytopenia, anemia, fever/infection, hepatic toxicity, peripheral neuropathy, GI toxicity |
|                             |       |    | Paclitaxel, 175 mg/m² D1 + carboplatin, AUC 5 D1 + PLD, 30 mg/m² D1 cycles 1, 3, 5, 7 | 3                | 8            | NS       | • More neutropenia, thrombocytopenia, anemia, fever/infection, GI toxicity |
|                             |       |    | Paclitaxel, 175 mg/m² D1 cycles 5–8 + carboplatin, AUC 5 D3 cycles 1–4, AUC 6 D1 cycles 5–8 + topotecan, 1.25 mg/m² D1–3 cycles 1–4 | 3                | 8            | NS       | • More anemia, hepatitis toxicity  
                                      |       |    |                                                                                 |                  |              |          | • Less peripheral neuropathy |
|                             |       |    | Paclitaxel, 175 mg/m² D1 cycles 5–8 + carboplatin, AUC 6 D8 cycles 1–4, D1 cycles 5–8 + gemcitabine, 1,000 mg/m² D1 and 8 cycles 1–4 | 3                | 8            | NS       | • More thrombocytopenia, anemia, hepatitis toxicity, pulmonary toxicity  
                                      |       |    |                                                                                 |                  |              |          | • Less peripheral neuropathy |
| Bolis et al, 2010           | III–IV| 326| Topotecan, 1.0 mg/m² D1–3 + paclitaxel, 175 mg/m² D3 + carboplatin, AUC 5 D3   | 3                | 6            | NS       | • More fatigue, anemia, leukopenia, neutropenia |
| du Bois et al, 2010         | I–IV  | 1,742| Paclitaxel, 175 mg/m² D1 + carboplatin, AUC 5 D1 + gemcitabine, 800 mg/m² D1 and 8 | 3                | 6            | Worse PFS  
                                      |       |    |                                                                                 |                  |              |                  | (P = .0044)  
                                      |       |    |                                                                                 |                  |              |          | NS OS  
                                      |       |    |                                                                                 |                  |              |          | • More grade 3/4 hematologic toxicity, fatigue  
                                      |       |    |                                                                                 |                  |              |          | • Worse QoL |
| OV-16/EORTC-55012/GEICO-0101 | IIB–IV| 819| Cisplatin, 50 mg/m² D1 cycles 1–4 + topotecan, 0.75 mg/m² D1–5 cycles 1–4 + paclitaxel, 175 mg/m² D1 cycles 5–8 + carboplatin, AUC 5 D1 cycles 5–8 | 3                | 8            | NS       | • More hematologic toxicities, thromboembolic events, nausea, vomiting, and hospitalizations  
                                      |       |    |                                                                                 |                  |              |          | • Less neurosensory effects and allergic reactions |
| NSGO, EORTC GCG, and NCIC CTG | II–IV | 887| Paclitaxel, 175 mg/m² D1 + carboplatin, AUC 5 D1 + epirubicin, 75 mg/m²         | 3                | 6–9          | NS       | • More anemia, febrile neutropenia, use of G-CSF, nausea, vomiting, mucositis  
                                      |       |    |                                                                                 |                  |              |          | • Less allergic reactions, arthralgia, myalgia  
                                      |       |    |                                                                                 |                  |              |          | • Worse QoL |

Abbreviations: AUC, area under the curve; D, day of cycle; G-CSF, granulocyte colony-stimulating factor; GI, gastrointestinal; NS, no significant difference between arms; OS, overall survival; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; QoL, quality of life.

*Each of the trials used the following regimen as comparator: paclitaxel, 175 mg/m² + carboplatin, AUC 5–6, both D1, q3wk x 6 cycles

†Total number of patients randomized, including those in the paclitaxel 175/carboplatin control arm.

‡Efficacy outcomes compared with paclitaxel 175/carboplatin.

§Test regimen compared with paclitaxel 175/carboplatin.

□Carboplatin dosing in the control arm of GOG-158 was AUC 7.5 (instead of AUC 5–6).

∥Paclitaxel dosing in the control arm of AGO-OVAR-3 was 185 mg/m² (instead of 175 mg/m²).

¶Carboplatin dosing in the control arm of HeCOG was AUC 7 (instead of AUC 5–6).

‖In GOG-0182-ICONS, 8 cycles was also used for the carboplatin/paclitaxel control arm.

¶In OV-16, 8 cycles was also used for the paclitaxel/carboplatin control arm.

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 19 Issue 2 | February 2021
References


